155 related articles for article (PubMed ID: 26553224)
1. Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma.
Huang C; Wang L; Yang X; Lai L; Chen D; Duan C
World J Surg Oncol; 2015 Nov; 13():314. PubMed ID: 26553224
[TBL] [Abstract][Full Text] [Related]
2. Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma.
Li H; Xiao W; Ma J; Zhang Y; Li R; Ye J; Wang X; Zhong X; Wang S
Int J Clin Exp Pathol; 2014; 7(11):7989-98. PubMed ID: 25550842
[TBL] [Abstract][Full Text] [Related]
3. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of STAT3 and HIF-1α in esophageal squamous cell carcinoma.
Zhao X; Tang YP; Wang CY; Wu JX; Ye F
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3351-3357. PubMed ID: 31081089
[TBL] [Abstract][Full Text] [Related]
5. Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3.
Qi C; Han T; Tang H; Huang K; Min J; Li J; Ding X; Xu Z
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085101
[TBL] [Abstract][Full Text] [Related]
6. [Overexpression of p-Stat3 and Mcl-1, and their correlation with differentiation and apoptotic resistance in esophageal squamous cell carcinoma].
Huo YQ; Ruan X; DU XL; Shang L; Cai Y; Xu X; Wang MR; Zhang Y; Fu SB
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):579-84. PubMed ID: 24314214
[TBL] [Abstract][Full Text] [Related]
7. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
[TBL] [Abstract][Full Text] [Related]
8. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
9. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma.
Liu L; Yang Z; Ni W; Xuan Y
Exp Mol Pathol; 2018 Apr; 104(2):134-139. PubMed ID: 29475036
[TBL] [Abstract][Full Text] [Related]
10. PTPLAD2 is a tumor suppressor in esophageal squamous cell carcinogenesis.
Zhu S; Wang Z; Zhang Z; Wang J; Li Y; Yao L; Mei Q; Zhang W
FEBS Lett; 2014 Mar; 588(6):981-9. PubMed ID: 24530685
[TBL] [Abstract][Full Text] [Related]
11. TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer.
Ou Y; Liu L; Xue L; Zhou W; Zhao Z; Xu B; Song Y; Zhan Q
J Genet Genomics; 2014 Oct; 41(10):529-37. PubMed ID: 25438697
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma].
Liu JR; Wang Y; Zuo LF; Li FL; Wang Y; Liu JL
Ai Zheng; 2007 May; 26(5):458-62. PubMed ID: 17672932
[TBL] [Abstract][Full Text] [Related]
13. TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma.
Zhang SS; Xie X; Wen J; Luo KJ; Liu QW; Yang H; Hu Y; Fu JH
Diagn Pathol; 2016 Jan; 11():14. PubMed ID: 26818094
[TBL] [Abstract][Full Text] [Related]
14. The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3β in Esophageal Squamous Cell Carcinoma.
Zhang HF; Chen Y; Wu C; Wu ZY; Tweardy DJ; Alshareef A; Liao LD; Xue YJ; Wu JY; Chen B; Xu XE; Gopal K; Gupta N; Li EM; Xu LY; Lai R
Clin Cancer Res; 2016 Feb; 22(3):691-703. PubMed ID: 26405196
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.
Wei R; Shang Z; Leng J; Cui L
J Cancer Res Ther; 2016; 12(4):1291-1297. PubMed ID: 28169242
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
17. The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma.
Zhang Y; Molavi O; Su M; Lai R
BMC Cancer; 2014 Oct; 14():791. PubMed ID: 25355139
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.
Gao S; Li S; Duan X; Gu Z; Ma Z; Yuan X; Feng X; Wang H
Mol Carcinog; 2017 Oct; 56(10):2301-2316. PubMed ID: 28574599
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of NS1-BP expression in esophageal squamous cell carcinoma].
Ren K; Qian D; Wang YW; Pang QS; Zhang WC; Yuan ZY; Wang P
Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):21-27. PubMed ID: 29365413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
